REFERENCES

1. CRA insights: life sciences. A landscape assessment of newborn screening (NBS) in Europe. 2021. Available from: https://media.crai.com/wp-content/uploads/2021/11/19130322/CRA-LS-Insights-NBS-Policy.pdf [Last accessed on 6 Jun 2024].

2. Loeber JG, Platis D, Zetterström RH, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen 2021;7:15.

3. Assessing the policy and access environment across European countries for SMA patients: identifying key areas for improvement. Available from: https://smatracker.eu/static/da46a45ac8edb35da49fad104f8eaafd/Tracker_of_Policy_and_Access_Environment_for_SMA_Patients_de4d7ac1c0.pdf [Last accessed on 6 Jun 2024].

4. Gowda VL, Fernandez-Garcia MA, Jungbluth H, Wraige E. New treatments in spinal muscular atrophy. Arch Dis Child 2023;108:511-7.

5. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 2019;29:842-56.

6. Spinal muscular atrophy. Available from: https://smatracker.eu/what-is-spinal-muscular-atrophy [Last accessed on 6 Jun 2024].

7. Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet 2021;14:11-25.

8. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723-32.

9. Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022;4:2.

10. SPR1NT: an open-label, single-arm clinical trial of presymptomatic patients with SMA. Available from: https://www.zolgensma-hcp.com/clinical-experiences/spr1nt-trial-efficacy/ [Last accessed on 6 Jun 2024].

11. #MDA2022 - Newborns treated with evrysdi standing, walking 1 year later. Available from: https://smanewstoday.com/news/mda-2022-presymptomatic-babies-treated-evrysdi-standing-walking-one-year-rainbowfish-trials/ [Last accessed on 6 Jun 2024].

12. Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 2021;20:832-41.

13. Finkel R, Farrar M, Vlodavets D, et al. FP.24 RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Neuromuscul Disord 2022;32:S85-6.

14. Antonaci L, Pera MC, Mercuri E. New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr 2023;182:2935-42.

15. Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2021;2:100346.

16. Wilson JMG, Jungner G. Principles and practice of screening for disease. 1968. Available from: https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 6 Jun 2024].

17. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-68.

18. Cances C, Vlodavets D, Comi GP, et al. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis 2022;17:300.

19. Annoussamy M, Seferian AM, Daron A, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol 2021;8:359-73.

20. Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020;7:1-13.

21. Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis 2021;16:47.

22. SMA NBS Alliance. Spinal muscular atrophy: screen at birth, save lives. 2021. Available from: http://www.eamda.eu/wp-content/uploads/2021/05/Spinal_muscular_atrophy_Screen_at_birth_save_lives_Whitepaper_SMA_NBS_Alliance_v1_26March21.pdf [Last accessed on 6 Jun 2024].

23. Morbidity and Mortality Weekly Report. CDC grand rounds: newborn screening and improved outcomes. 2012. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a2.htm [Last accessed on 6 Jun 2024].

24. IQWIG-Bericht - Nr. 891. Neugeborenenscreening auf 5q-assoziierte spinale Muskelatrophie. Available from: https://www.iqwig.de/download/s18-02_neugeborenenscreening-auf-5q-assoziierte-sma_abschlussbericht_v1-0.pdf [Last accessed on 6 Jun 2024].

25. Boemer F, Caberg JH, Dideberg V, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 2019;29:343-9.

26. Chen X, Sanchis-Juan A, French CE, et al. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med 2020;22:945-53.

27. WEBINAR. Newborn screening techniques for SMA. Available from: https://www.youtube.com/watch?v=Jh0iJLL_7Hs [Last accessed on 6 Jun 2024].

28. EURORDIS Rare Diseases Europe. Available from: https://www.eurordis.org/rare-barometer/english/ [Last accessed on 6 Jun 2024].

29. Rare disease patients’ opinion on the future of rare diseases: a rare barometer survey for the rare 2030 foresight study. Available from: https://download2.eurordis.org/rbv/rare2030survey/reports/RARE2030_survey_public_report_en.pdf [Last accessed on 6 Jun 2024].

30. Global leaders convene in London: advancing newborn sequencing on an international scale. 2023. Available from: https://genomes2people.medium.com/global-leaders-convene-in-london-advancing-newborn-sequencing-on-an-international-scale-590c8af350d7 [Last accessed on 6 Jun 2024].

31. ICoNS. Available from: https://www.iconseq.org/publications [Last accessed on 6 Jun 2024].

32. Newborn screening: toward a uniform screening panel and system. Available from: https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/newborn-uniform-screening-panel.pdf [Last accessed on 6 Jun 2024].

33. Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther 2023;12:1205-20.

34. Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands. Value Health 2022;25:1696-704.

35. Dangouloff T, Thokala P, Stevenson MD, et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscul Disord 2024;34:61-7.

36. Liu G, Lipari P, Mollin A, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Hum Mol Genet 2024;33:211-23.

37. Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease. 2018. Available from: https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease [Last accessed on 6 Jun 2024].

38. World Health Organization. Standards for improving the quality of care for small and sick newborns in health facilities. Available from: https://iris.who.int/bitstream/handle/10665/334126/9789240010765-eng.pdf?sequence=1 [Last accessed on 6 Jun 2024].

39. EURORDIS Rare Diseases Europe. Key principles for newborn screening. Available from: https://download2.eurordis.org/documents/pdf/eurordis_nbs_position_paper.pdf [Last accessed on 6 Jun 2024].

40. Health Resources & Services Administration. Recommended uniform screening panel. Available from: https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp [Last accessed on 6 Jun 2024].